Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NOTICE
October 22, 2001
- Usefulness of Aspirin Underlined: Dr Hennekens
October 22, 2001
- NHI Price Ceiling to Be Set: Reform Proposal -1-
October 22, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 22, 2001
- NHI Price Ceiling to Be Set: Reform Proposal -2-
October 22, 2001
- 60th Annual Meeting of the Japanese Cancer Association
October 22, 2001
- MOF Proposes 30% Copayment Rate for All Patients
October 22, 2001
- COPD Prevalence Reaches 8.5% in Japanese over 40: Dr Fukuchi
October 22, 2001
- Drug Companies Need to Enhance Int'l Competitiveness: JPA Congress
October 22, 2001
- South Africa Invites Japanese Firms to Come to Conduct Clinical Trials
October 22, 2001
- Market Economy to Turn Healthcare into Darwinian Jungle: Dr Itouji of JMA
October 22, 2001
- RESEARCH & DEVELPMENT NEWS IN BRIEF
October 22, 2001
- Korosho Proposes to Raise Monthly Upper Limit of Copayments
October 22, 2001
- WORLD NEWS IN BRIEF
October 22, 2001
- 10 New Themes for Basic Research Promotion Selected
October 22, 2001
- NEW PRODUCTS NEWS IN BRIEF
October 22, 2001
- REGULATORY NEWS IN BRIEF
October 22, 2001
- Abbereviationon of the week
October 22, 2001
- Not to Expect Gov't to Adopt ATP Soon: Mr Butler of PhRMA -1-
October 22, 2001
- Benefits of INNOVA2000 Explained: GE Yokogawa Seminar
October 22, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…